Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

312

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

May 15, 2026

Study Completion Date

October 15, 2027

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

with or without venetoclax

Bcl-2 inhibitor

Trial Locations (1)

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER